With the purchase, Syneos Health seeks to strengthen connections with the rapidly growing pre-revenue biopharmaceutical market, and expand global reach.
Acquisition of Clindata’s human health biometrics division is expected to increase Synteract’s geographical footprint along with the adaptability of its biometrics services solutions.
Phastar is building up its data science group as AI and machine learning ‘are rapidly modernizing clinical trials’ and Synteract boosts its centers of development in oncology and rare/orphan diseases, among other people on the move this month.
Synteract adds to its therapeutic centers of development, Sterling Pharma continues growth in the US, and WCG’s site division sees the addition of several executives, among other people on the move this month.
Synteract is opening a new office in Swansea, Wales in response to increased demand across its core therapeutic areas for both full-service work and more consultative, standalone projects, says CEO.
Synteract’s clients will benefit from a single source model, says CEO, following the acquisition of KinderPharm, a PA-based CRO focused on all phases of pediatric drug development.
As aging populations grow and treatment paradigms shift, the industry must prepare for greater challenges in the rare disease clinical trial space, says CRO executive.
Ignoring pediatric considerations is no longer an option for the development of new medicines – though clinical trials in children are still not widely accepted by society, explains industry executive.
Synteract has acquired the dermatology CRO Cu-Tech, opening a fifth center of development as part of its strategy to develop “highly-expert therapeutic areas of focus,” says CCO.
